Publication
Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity
| dc.contributor.author | Fangueiro, JF | |
| dc.contributor.author | Andreani, T | |
| dc.contributor.author | Egea, MA | |
| dc.contributor.author | Garcia, ML | |
| dc.contributor.author | Souto, SB | |
| dc.contributor.author | Silva, AM | |
| dc.contributor.author | Souto, EB | |
| dc.date.accessioned | 2014-02-14T13:05:40Z | |
| dc.date.available | 2014-02-14T13:05:40Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | In the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5wt% of CTAB. | por |
| dc.identifier.citation | Int J Pharm. 2014;461(1-2):64-73 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.23/576 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Elsevier | por |
| dc.relation | CATIONIC LIPID NANOMEDICINES FOR DIABETIC RETINOPATHY | |
| dc.relation | NanoLaseRelief: Integrando nanotecnologias no alívio da dor na terapia laser de lesões vasculares | |
| dc.subject | Olho/metabolismo | por |
| dc.subject | Nanopartículas | por |
| dc.subject | Lípidos | por |
| dc.subject | Soluções Oftálmicas | por |
| dc.title | Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | CATIONIC LIPID NANOMEDICINES FOR DIABETIC RETINOPATHY | |
| oaire.awardTitle | NanoLaseRelief: Integrando nanotecnologias no alívio da dor na terapia laser de lesões vasculares | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F80335%2F2011/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F60640%2F2009/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/5876-PPCDTI/PTDC%2FSAU-FAR%2F113100%2F2009/PT | |
| oaire.fundingStream | SFRH | |
| oaire.fundingStream | 5876-PPCDTI | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |
| relation.isProjectOfPublication | 36949c3d-10e1-429f-a21e-b3a48b6dded5 | |
| relation.isProjectOfPublication | 58c0916a-6dba-4cca-995f-68bf278244b1 | |
| relation.isProjectOfPublication | ebcdcbcf-715f-4aa0-bc8c-b0c16b714695 | |
| relation.isProjectOfPublication.latestForDiscovery | 58c0916a-6dba-4cca-995f-68bf278244b1 |